MinervaX, a privately held Danish biotechnology company,
today announces that EMA has awarded PRIME status for its vaccine against Group B Streptococcus (GBS).
PRIME is aimed at enhancing support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier.

Press inquiries should be adressed to: